TABLE 1.
Demographics and antiretroviral regimen components for the 14 study women
| Characteristic | Value |
|---|---|
| At enrollment | |
| Median (IQR)a age (yrs) | 27.5 (22.0, 30.0) |
| Median (IQR) gestational age (wks) | 19.5 (13.5, 27.5) |
| Median (IQR) weight (kg) | 83.8 (68.9, 107.3) |
| Median (IQR) body mass index (kg/m2) | 31.4 (25.4, 41.2) |
| Median (range) HIV-1 RNA (copies/ml) in: | |
| Blood plasma | 1,360 (85, 195,000) |
| Genital tract | <400 (<400, 400,000) |
| Median (range) CD4+ T-cell count | |
| (cells/mm3) | 456 (230, 1,006) |
| Race or ethnicity | |
| No. (%) African-American | 9 (64) |
| No. (%) Caucasian | 3 (21) |
| No. (%) Hispanic | 2 (14) |
| No. (%) with indicated ARV experience | |
| First regimen | 10 (71) |
| Second regimen | 2 (14) |
| Multiple regimens | 2 (14) |
| No. (%) receiving indicated NRTI | |
| 3TC, 150 mg twice daily | 14 (100) |
| ZDV, 300 mg twice daily | 13 (93) |
| TDF, 300 mg once daily | 3 (21) |
| d4T, 40 mg twice daily | 1 (7) |
| ddI EC, 400 mg once daily | 1 (7) |
| No. (%) receiving indicated NNRTI and PI | |
| NVP, 200 mg twice daily | 1 (7) |
| LPV-RTV, 400 and 100 mg twice daily | 7 (50) |
| NFV, 1,250 mg twice daily | 6 (43) |
| Median (range) HIV-1 RNA (copies/ml)b in blood plasma during: | |
| Second trimester (n = 31) | 205 (<50, 11,300) |
| Third trimester (n = 52) | 67 (<50, 7,755) |
| Postpartum (n = 20) | <50 (<50, 13,181) |
| Median (range) HIV-1 RNA (copies/ml)b in genital tract | |
| Second trimester (n = 24) | <400 (<400, 33,000) |
| Third trimester (n = 33) | <400 (<400, 52,000) |
| Postpartum (n = 8) | <400 (<400, 26,000) |
a
IQR, interquartile range.
b
Data exclude enrollment values.